AstraZeneca X Mindpeak: Transforming Early Breast Cancer Detection with AI

We are pleased to announce that Mindpeak will be exhibiting at AACR 2026 in collaboration with Revolune.

At this year’s meeting, we will present a joint approach to simplifying spatial biology workflows by combining Revolune’s multiplex immunofluorescence (mIF) reagents with Mindpeak’s AI-powered image analysis - PhenoScout.

By integrating staining and analysis into a streamlined workflow, researchers can generate high-quality multiplex tissue data and efficiently derive meaningful biological insights. This supports key applications such as biomarker discovery and translational cancer research.

We believe that reducing complexity is essential to accelerating the adoption of spatial biology technologies. Together with Revolune, our goal is to make advanced multiplex workflows more accessible, scalable, and practical for real-world use.

For more details, please read the full press release:
https://lnkd.in/dSRZaEAw

If you are attending AACR 2026, we invite you to visit us at booth #1660

We are excited to announce a global reseller agreement with Leica Biosystems, a Danaher company and global leader in digital pathology. This partnership marks an important step in expanding access to Mindpeak’s AI-powered pathology solutions worldwide.

By integrating our AI applications into the Aperio HALO AP platform and Aperio AI Store, laboratories and biopharma teams can seamlessly bring advanced biomarker and tissue analysis into their daily workflows -supporting greater efficiency, reproducibility, and scalability.

Together, we aim to accelerate biomarker discovery and enable smarter decisions across the drug development lifecycle.

Read the full Press Release here: https://www.einpresswire.com/article/900262524/mindpeak-announces-global-reseller-agreement-with-leica-biosystems-to-expand-access-to-ai-pathology-solutions

Mindpeak has been granted its first patent, marking an important milestone in the company’s mission to advance AI-powered pathology and precision diagnostics.

The patent protects a novel method for training artificial intelligence systems to accurately identify and classify different cell types in tissue samples. This technology addresses a critical requirement for reliable cancer diagnostics and reinforces the role of AI as a dependable decision-support tool for pathologists.

The patent has been issued across 18 European Union member states and validated in the United Kingdom, highlighting the originality, robustness, and clinical relevance of Mindpeak’s approach to digital pathology.

This achievement reflects the dedication and expertise of Mindpeak’s research, development, and engineering teams, whose work continues to advance the capabilities of medical AI.

For further information, please refer to the full press release:
https://www.globenewswire.com/news-release/2025/12/10/3202933/0/en/Mindpeak-Secures-First-Patent-for-Advanced-AI-Method-in-Digital-Pathology.html

‍